

# The Place and Prognostic Value of TERT Promoter Mutation in Molecular Classification in Grade II-III Glial Tumors and Primary Glioblastomas

Neslihan Kaya TERZI<sup>1</sup> , Ismail YILMAZ<sup>2</sup> , Aysim Buge OZ<sup>3</sup> 

Department of Pathology, <sup>1</sup>University of Health Sciences Gaziosmanpasa Research and Training Hospital, ISTANBUL, TURKEY, <sup>2</sup>University of Health Sciences, Sultan 2. Abdulhamid Han Research and Training Hospital, ISTANBUL, TURKEY, <sup>3</sup>University of Cerrahpasa, Cerrahpasa Medical Faculty, ISTANBUL, TURKEY

The study was presented at 31<sup>st</sup> European Congress of Pathology, 7-11 September 2019 at the Nice Acropolis Convention Centre.

## ABSTRACT

**Objective:** Diffuse gliomas, the most common primary malignant brain tumors, have been classified by the World Health Organization as class II-IV gliomas. After 2016, two mutations in the promoter region of the telomerase reverse transcriptase (*TERT*) gene were identified in addition to the IDH, 1p / 19q, and ATRX status.

**Material and Method:** We identified 84 patients with grade II-IV glioma with IDH, ATRX, 1p / 19q and *TERT* status. All tumor samples were subjected to molecular genetic screening (Sanger sequencing for IDH and *TERT* mutations, fluorescence in situ hybridization for 1p/19q status) after histological diagnosis (immunohistochemistry for IDH1 R132H, ATRX, and p53) for a more precise molecular diagnosis. The confidence intervals were calculated at the 95% confidence level, and differences at  $p < 0.05$  were considered statistically significant.

**Results:** Primary glioblastomas had the highest frequency of *TERT* promoter mutations (25 of 28, 89.2%,  $p=0.006$ ) followed by oligodendrogliomas (29 of 35, 82.8%,  $p<0.001$ ) while astrocytomas showed the lowest frequency (3 of 15, 20%,  $p=0.107$ ), and the positivity significantly differed among these three groups ( $p<0.001$ ). *TERT* promoter mutations were more frequent in patients older than 55 years of age at diagnosis ( $p=0.023$ ). The group with *TERT* promoter mutations, and without IDH mutations showed the worst overall survival. However, the presence of both *TERT* promoter and IDH mutations, which resembled oligodendroglial progression, showed best overall survival ( $p=0.042$ ).

**Conclusion:** The discovery of *TERT* promoter mutations in numerous gliomas has opened the door for a better molecular classification of gliomas, and *TERT* status is associated with survival. Further studies will help in elucidating the value of *TERT* promoter mutations as biomarkers in clinical practice, and eventual therapeutic targets.

**Keywords:** Diffuse glioma, Primary glioblastoma, *TERT* p, Promoter mutation, Survival

## INTRODUCTION

Diffuse gliomas, the most common primary malignant brain tumors, have been classified by the World Health Organization (WHO) as class II-IV gliomas (1). After 2016, increasing and broad characterization of the genomic structure of gliomas has led to the identification of genetic and epigenetic markers useful for the molecular classification of these tumors (2). In addition to the IDH, 1p / 19q, and ATRX status, two mutations in the promoter region of the telomerase reverse transcriptase (*TERT*) gene were frequently identified (3). The mutation in the promoter region of this gene was first discovered in melanoma (4). In 2013, *TERT* promoter mutations were included in the molecular classification of gliomas (3). *TERT* is an important unit of the telomerase complex. It is known that upregulation of *TERT* increases telomerase activity, the basic survival ability of cancer cells, which allows for

unlimited expansion of telomeres, and immortalization of cells (5). The mutation takes place in one of the two hot spots of the *TERT* gene, C228T and C250T, as C-T transition (6).

*TERT* mutations are usually investigated by sequencing or real-time PCR (7), and *TERT* promoter mutations occur in 70-80% of glioblastomas (GBM), 95% of oligodendrogliomas (OD), and 10-25% of astrocytomas (5). *TERT* promoter mutations are significantly inversely proportional to *IDH1* / 2 mutations (8). Changes in *TERT* and IDH are not only associated with specific histological glioma subgroups, but also are associated with a variable prognosis (9).

The literature on telomere-related mechanisms with glioma is rapidly increasing. Their prognostic and predictive roles are very interesting and may guide the clinical management

(*Turk Patoloji Derg* 2022, 38:90-98)

Received : 28.05.2021 Accepted : 24.07.2021

**Correspondence:** Neslihan KAYA TERZI

University of Health Sciences, Gaziosmanpasa Research and Training Hospital, Department of Pathology, ISTANBUL, TURKEY  
E-mail: neslihan\_kaya88@hotmail.com Phone: +90 555 604 58 68

of glioma patients. Yet, there are no studies investigating the distribution and significance of *TERT* promoter mutations in the WHO 2016 classification (10).

In the study conducted at Mayo Clinic, cases with 1 / 19q co-deletion, *IDH* mutation and *TERT* promoter mutation (triple-positive) were associated with an oligodendroglial phenotype and showed better overall survival (OS). Low-grade tumors (II and III) showing *TERT* and *IDH* mutations without 1p19q co-deletion tended to have a prognosis similar to triple-positive cases (11). However, patients without *TERT* and *IDH* mutations and those with 1p/19q co-deletion had very aggressive tumors and poor survival. Patients with wild-type (WT) *TERT*, *IDH*, and persevered 1p19q (triple negative) were associated with GBM, and had worse prognosis than triple-positive gliomas, but had a better prognosis than in patients with *TERT* mutations only (12).

## MATERIALS and METHODS

This study was approved by the medical ethics committee of the University of Health Sciences, Samatya Training Hospital (Approval No.: 06.07.2018 / 1337), and it was conducted according to the Declaration of Helsinki Principles.

### Study Population

We identified 84 patients (32 females and 52 males) with grade II-IV glioma with known *IDH*, *ATRX*, 1p / 19q and *TERT* status. Fifty-seven patients had WHO grade II-III tumors (24 oligodendrogliomas (OD), 14 anaplastic ODs, 13 astrocytomas, 5 anaplastic astrocytomas, and 1 anaplastic oligoastrocytoma with a low grade glioma component), and the remaining 27 samples represented high grade glioma (WHO grade IV/GBM) (Table I).

All tumor samples were subjected to molecular genetic screening after histological diagnosis for a more precise / molecular diagnosis (13, 14). Tumors in the astrocytoma group were characterized by detectable immunoreactivity for *IDH1* (R132H), *p53* and loss of immunoreactivity for *ATRX* (15). All tumors in the OD group had *IDH1* mutation (R132H) and 1p / 19q co-deletion. GBMs were *IDH* wild type (*IDH*-WT) (1).

### Immunohistochemistry (IHC), Assessment of *TERT* promoter and *IDH* Mutation, Fluorescence in situ Hybridization (FISH)

Immunohistochemistry (IHC) was performed on at least one representative block using primary antibody against the following antigens- *IDH1* R132H (Dianova, dilution

**Table I:** Clinicopathological variables of the 84 diffuse glioma patients.

Demographics	n (%)
<b>Gender</b>	
Male	52 (61.9)
Female	32 (38.1)
<b>Age (y), mean <math>\pm</math> SD</b>	
$\leq 55$	65 (77.3)
$> 55$	19 (22.6)
<b>Tumor location</b>	
Frontal	48 (65.7)
Midline	16 (21.9)
Others	9 (12.3)
<b>WHO 2016 diagnosis</b>	
Diffuse astrocytoma, <i>IDH</i> -mutant	10 (11.9)
Diffuse astrocytoma, <i>IDH</i> -wildtype	3 (3.5)
Anaplastic astrocytoma, <i>IDH</i> -mutant	4 (4.7)
Anaplastic astrocytoma, <i>IDH</i> -wildtype	0 (0)
Oligodendroglioma, <i>IDH</i> -mutant & 1p/19q-codeleted	23 (27.3)
Anaplastic oligodendroglioma, <i>IDH</i> -mutant & 1p/19qcodeleted	14 (16.6)
Oligodendroglioma, NOS	1 (1.1)
Anaplastic oligoastrocytoma, <i>IDH</i> -mutant & 1p/19qcodeleted	1 (1.1)
Glioblastoma, <i>IDH</i> -mutant	0 (0)
Glioblastoma, <i>IDH</i> -wildtype	28 (33.3)
<b>Surgery</b>	
Biopsy only	10 (11.9)
Total resection	74 (88)
<b>Adjuvant treatment</b>	
None	4 (4.7)
Chemoradiation	80 (95.2)
<b>Survival outcome</b>	
Alive	61 (72.6)
Deceased	19 (22.6)

SD: Standard deviation

1:40), *ATRX* (Sigma, dilution 1:300), and *p53* (Dako, dilution 1:50). Cases showing cytoplasmic positivity for *IDH1* in tumor cells were considered positive. Loss of nuclear staining for *ATRX* in tumor cells ( $>90\%$ ) was considered positive for *ATRX* mutation. Nuclear positivity for *p53* in  $>10\%$  tumor cells was considered positive (16).

Mutations in the promoter region of *TERT* gene (chr5, 1,295,228C>T and 1,295,250C>T) and exon 4 of *IDH1* and *IDH2* genes (well-known hotspot regions for oncogenic mutations) were analyzed by PCR-based direct sequencing using representative formalin-fixed paraffin-embedded tumor samples. Tumor targets were manually microdissected from 5- $\mu$ m thick unstained histological sections. After deparaffinization and rehydration, DNA was isolated from each target using QIAamp DNA FFPE Tissue Kit (50) (catalog #: 56404) (QIAGEN, Hilden, Germany) in accordance with the manufacturer's instructions. DNA concentrations of samples were assessed spectrophotometrically using a Nanodrop 1000 spectrophotometer (Thermo Scientific, USA). PCR was performed in a Thermal Cycler (ABI, Applied Biosystems, USA) using HotStarTaq DNA Polymerase kit (catalog #: 203205) (QIAGEN, Hilden, Germany), and appropriate primers (*TERT* -Forward: 5'CAGCGCTGCCTGAAACTC'3, *TERT* -Reverse: 5'GTCCTGCCCCTTACCTT'3, *IDH1* exon 4-Forward: 5'CCAAGTCACCAAGGATGCTG'3, *IDH1* exon 4-Reverse: 5' TCACATTACTGCCAACATGACTT'3, *IDH2* exon 4-Forward: 5' CCGTCTGGCTGTGTGTGTTG'3, and *IDH2* exon 4-Reverse: 5' AGTCTGTCGCCTTGTACTGC'3).

PCR reactions were run as total volume of 50  $\mu$ l reaction mixtures consisting of nuclease free water, 5  $\mu$ l 10x PCR Buffer, 10  $\mu$ l Q solution (for *TERT*), 1.5  $\mu$ l 10 mM dNTP mix (ABI, Applied Biosystems, USA), 2  $\mu$ l 25 mM MgCl<sub>2</sub> (for *IDH1* and *IDH2*), 7  $\mu$ l (for *TERT*) and 6  $\mu$ l (for *IDH1* and *IDH2*) of each primer (4pmol/ $\mu$ l), 0.25  $\mu$ l of Hot Start Taq DNA polymerase, and 50 ng of each tumor DNA. After an initial denaturation at 95°C for 15 minutes, 42 cycles were performed of 30 seconds denaturation at 95°C, 30 seconds annealing at 55°C (for *TERT*), and at 58°C (for *IDH1* and *IDH2*), and 45 seconds extension at 72°C, followed by a final extension of 10 minutes at 72°C. The intensity of the PCR products were checked by running 5  $\mu$ l of each PCR reaction with 2  $\mu$ l of loading dye on a 2% agarose gel. Reagent contamination control was achieved by examining the lane for "No DNA" blank tube. Then, all succeeded PCR products were purified using the QIAquick PCR Purification Kit (catalog #: 28106) (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. The purified amplicons were submitted to direct sequencing in both directions (forward and reverse) using reagents from the Big Dye Terminator v3.1 Cycle Sequencing kit (ABI, Applied Biosystems, USA) in accordance with the manufacturer's protocol. After ethanol precipitation, subsequent products were run on the ABI-3730 (48 capillary) automatic sequencer (Applied Biosystems, USA).

Bidirectional sequence traces were analyzed with SeqScape® Software v3.0 (Applied Biosystems, USA), and manually reviewed.

FISH analysis was performed on 5-micron-thick formalin fixed paraffin-embedded tissue samples. Deparaffinization, pre-hybridization and hybridization steps were conducted according to the datasheet. One hundred tumors cells were analyzed on the fluorescent microscope (Olympus BX61; Olympus Optical, Japan). The cells were captured on a computer system with a digital camera (XLMM, Dage-MTI, IN, USA), and compatible software (Duet®, Bioview Ltd., Israel). Dual-color paired probes for 1p and 1q (1p36 Spectrum Orange and 1q25 Spectrum Green, Vysis LSI probes, Abbott Molecular, Des Plaines, IL) were hybridized simultaneously on one slide, and similarly those for 19q, and 19p (19q13 Spectrum Orange and 19p13 Spectrum Green, Vysis LSI probes, Abbott Molecular, Des Plaines, IL) were used on a separate slide. A proportion is used due to the fact that a significant number of nuclei would have reduced comparison/control (green) signals because of tissue sectioning removing portions of the nuclei. Based on laboratory experience, a proportion <0.80 was considered as a deletion. The ratio of SpectrumOrange to SpectrumGreen signals (total orange/total green) was calculated.

### Statistical Analysis

Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 21.0. (IBM Corp., Armonk, NY). Descriptive statistics were used to describe the data. Normal distribution was tested by the Kolmogorov-Smirnov and Shapiro-Wilk tests. Non-parametric data were compared using the Chi-square test. The Kaplan-Meier method was used for survival analysis, and the log-rank test (Mantel-Cox) was performed to compare the survival curves between the groups. The confidence intervals were calculated at the 95% confidence level and differences at  $p < 0.05$  were considered statistically significant.

## RESULTS

### Clinicopathologic Demographics

A total of 84 patients consisting of 52 men (61.9%) and 32 women (38.1%) were recruited. Their mean age was 44.68  $\pm$  14.12 years (range 12–82 years). The mean duration of follow-up was 24-60 months. There were 65 patients (77.3%) aged less than 55 years, and 19 patients (22.6%) older than 55 years. The WHO 2016 revised diagnosis of the study group was as follows: 10 diffuse astrocytomas - IDH-mutant (11.9%); 3 diffuse astrocytomas- IDH-WT (3.5%); 4 anaplastic astrocytomas- IDH-mutant (4.7%); 23 ODs-IDH-mutant, and 1p/19q codeleted (27.3%); 14

anaplastic ODs, IDH-mutant & 1p/19q-codeleted (16.6%); 1 OD NOS (1.1%); 1 anaplastic oligoastrocytoma (1.1%), and 28 GBM-IDH-WT (33.3%). Biopsy was carried out only in 10 patients (11.9%), and debulking surgery was performed in 74 patients (88%). 80 patients (95.2%) were treated with some form of adjuvant radiotherapy and/or chemotherapy, while 4 (4.7%) patients did not receive any adjuvant radio-chemotherapy. 61 patients were alive (72.6%) while 19 patients (22.6%) died (Table I).

### TERT Promoter Mutations and Alterations in Other Genes

Overall, *TERT* promoter mutations were present in 57 of 84 (67.9%) gliomas [20 (60.6%) in grade II, 12 (66.6%) in grade III, and 25 (92.5%) in grade IV]. The C228T mutation was detected in 42 tumors (53.8%), whereas the C250T mutation was found in 15 cases (19.2%), supporting the predominance of the C228T mutation in glioma. Primary glioblastomas had the highest frequency of *TERT* promoter mutations (25/28; 89.2%,  $p=0.006$ ) followed by oligodendrogliomas (29/35; 82.8%,  $p<0.001$ ), while astrocytomas showed the lowest frequency, with 3 out of 15 (20%,  $p=0.107$ ) samples showing mutations (Table II). *TERT* promoter mutations were found to be associated with high grade (grade III/IV) tumors when compared to lower grade (grade II) lesions ( $p<0.033$ ), and were more frequent in patients older than 55 years of age ( $p=0.023$ ). A statistically significant association was observed between the *TERT* mutation and the diagnosis ( $p<0.001$ ). We performed post hoc power analysis by G\*Power 3.1.9.2. The Type II error ( $\beta$ ) probability was less than 0.01 (power  $>0.99$ ) for the combined diagnostic algorithm (Figure 1).

*IDH* gene mutations were present in 44 tumors (42 of these being *IDH1* R132H mutations). Twenty-nine of these (corresponding to oligodendrogliomas) harbored a concomitant 1p/19q co-deletion, and all of them except three were also *TERT* promoter mutant.

The *TERT* p mutation and *IDH* mutation were more highly associated compared to *TERT* p with IDH-WTs ( $P<0.001$  and  $p=0.655$ , respectively). However, in oligodendroglial tumors, *TERT* promoter and *IDH* mutations occurred together ( $p<0.001$ ). 24 of 26 IDH/*TERT* double mutant tumors had the 1p/19q co-deletion. In primary glioblastomas, there were no *IDH* mutations, as expected. In astrocytomas, *TERT* promoter and *IDH* mutations were both found in only 2 of 15 cases (Figure 2).

Moreover, *TERT*p and *TP53* mutations in low-grade and anaplastic gliomas were mutually exclusive, where none and 5.5% of *TERT* mutated tumors harbored *TP53* mutations, respectively. A statistically significant association was observed between the *TERT* mutation and *p53* mutation ( $p<0.001$ ).

*TERT* promoter mutations were mutually exclusive with *ATRX* deficiency. However, no statistically significant association was observed between the *TERT* mutation and *ATRX* mutation ( $p=0.533$ ).

### Effect of TERT Promoter Mutations on Survival

Results of the Kaplan-Meier survival analysis are shown in Figure 3A,B.


The overall cumulative survival in cases with *TERT* mutation was 64.94 months (95% CI=55.58-74.31) and overall cumulative survival in cases without *TERT* mutation was 46.80 months (95% CI=37.71-55.89) ( $p=0.870$ ) (Figure 3B). Patients carrying the C250T mutation had slightly longer survival compared to patients with the C228T mutation (78.5% and 76.9%).

Moreover, the *TERT* mutation frequency, both C228T and C250T, increased with age:  $<40$  years: 65.5% (19/29); 40-55 years: 66.6% (20/30), and  $>55$  years: 94.7% (18/19). Compared to patients with WT- *TERT*, younger patients with *TERT* mutation survived longer, but patients with *TERT* mutation who were aged  $>55$  years had shorter survival.


**Table II:** The frequency of *TERT*p mutations.

Diagnosis	C228T mutation	C250T mutation	Both <i>TERT</i> mutations
	n (%)	n (%)	n (%)
OD, <i>IDH</i> mutant	18/23 (78.2)	5/23 (21.7)	23/26 (88.4)
OD, <i>IDH</i> wildtype	1/2 (50)	1/2 (50)	2/4 (50)
A-AA, <i>IDH</i> mutant	1/2 (50)	1/2 (50)	2/12 (16.6)
A, <i>IDH</i> wildtype	1/1 (100)	0 (0)	1/2 (50)
GBM, <i>IDH</i> wildtype	19/25 (76)	6/25 (24)	25/28 (89.2)

OD: Oligodendroglioma, A: Astrocytoma, AA: Anaplastic astrocytoma, GBM: Glioblastoma.



**Figure 1:** Specificity and sensitivity of TERT mutation in glioblastoma, oligodendroglioma / anaplastic oligodendroglioma, and astrocytoma / anaplastic astrocytoma.




**Figure 2:** Molecular classification of diffuse glioma and frequency of each subgroup in our study.

Stratification of the patients based on the mutational status of *TERT* promoter and *IDH* resulted in three groups with different overall survival. The group with *TERT* promoter mutations and no *IDH* mutations had the worst overall survival (median survival 12.29 months), the 2nd worst overall survival rate was the group without *TERT* and *IDH* mutations (median survival 24 months). Best overall survival was associated with the presence of both *TERT* promoter and *IDH* mutations (median survival 38.07 months), which resembles oligodendroglial progression ( $p=0.042$ ).

Survival analysis in patients with primary glioblastomas did not reveal any effect of the *TERT* promoter mutations. Both patients with and without *TERT* promoter mutations had a median survival of 12 months (Figure 3A).

In diffuse and anaplastic gliomas that showed *TERT* promoter mutations were associated with poor survival while 1p/19q co-deletions had a favorable effect. Survival in gliomas with a *TERT* mutation and 1p19q co-deletion (median survival 58.2 months) was higher than in those without *TERT* mutation and 1p19q codeletion (median survival 42 months).



**Figure 3:** Survival times of anaplastic oligodendroglioma and glioblastoma cases (A). Survival times of cases with TERT mutation (B).

## DISCUSSION

Gliomas are the most common and aggressive primary brain tumors in adults (2). For diffuse gliomas, *IDH* mutations and 1p/19q co-deletion constitute the main components of the integrated WHO 2016 diagnosis. Molecular classifications proposed in the literature include the combination of the *IDH* mutations, the 1 p / 19q co-deletion, and the telomere maintenance mechanism as defined by alterations in *TERT* (15). To determine whether the *TERT* status provides additional prognostic information, we analyzed the relationship between overall survival in glioma patients classified according to the WHO 2016 criteria in our cohort.

Recent studies have shown that this classification has certain limitations for precise prediction of clinical outcomes and strategies for gene target therapy (16). Therefore, a more objective glioma classification is needed to guide diagnosis and treatment strategies.

Telomeres are structures at the end of eukaryotic chromosomes and are responsible for the deterioration of chromosomes, end-to-end fusion, and protection from rearrangement (17). Telomerase maintains the appropriate telomere length by adding repeated telomeric sequences to the 3' ends of the telomeres. Abnormal telomerase activity plays a role in the initiation and development of cancer and other diseases related to aging (18). *TERT* is overexpressed in many human cancers (19). *TERT* promoter mutations were first found in melanoma and were thought to represent the tumorigenic mechanism (16).

The discovery of *TERT* p mutations in numerous gliomas has opened the door for a better molecular classification of gliomas in 2013 (20, 21). *TERT* promoter mutations occur in 70-80% of glioblastomas, 95% of oligodendrogliomas, and 10-25% of astrocytomas (5, 7, 11).

The prevalence of *TERT* promoter mutations associated with various histological categories was similar to other studies (22, 23). As expected, *IDH*-mutant tumors were prevalent predominantly in younger adults, while all *IDH*-WT/ *TERT* -mutant tumors apart from a single pediatric tumor occurred in adults. Our findings are consistent with the concept that *IDH*-WT/ *TERT*-mutant diffuse gliomas represent a clinicopathological part of primary glioblastomas and their precursors (24, 25). In any case, inclusion of *TERT* promoter mutation analysis into a diagnostic molecular panel shifts the vast majority of otherwise marker-negative diffuse gliomas into a biologically plausible category. Furthermore, *TERT* promoter mutation status is of prognostic significance not only in diffuse gliomas with non-glioblastoma histology (11, 25), but also in glioblastoma (10, 26). The present study demonstrates that adding the *TERT* promoter mutation status to standard markers, as suggested in the literature, results in a precise molecularly directed classification with *IDH*-WT/ *TERT* -mutant tumors representing the primary glioblastoma group (27).

Age was another parameter for survival. Patients aged >55 years who had *TERT* mutation had worse survival compared to patients without the mutation.

In the whole cohort, patients with C250T mutations tended to have longer survival compared to patients with C228T mutations. We found that occurrence of the C228T and C250T mutations were mutually exclusive in our cohort, and that C228T (84.2%) was more common than C250T (15.8%).

With rare exceptions, *TERT* promoter mutations (8), which lead to an increase in telomerase expression, and inactivating mutations in the thalassemia/mental retardation syndrome X-linked (*ATRX*) gene, are mutually

exclusive, and are associated with different molecular tumor subclasses (28). Our study was the exception for mutual relationship of *ATRX* and *TERT* mutations, as we could not find any significant relationship ( $p=0.533$ ). On the other hand, our study demonstrated that *TERT* promoter mutations have a significant inverse association with *P53* mutation ( $p<0.001$ ), similar to previous studies (17).

*TERT* promoter mutations have been reported to be associated with aggressive behavior and poor outcome in various types of cancers (3). In this study, prognosis in glioblastoma cases with *TERT* mutation was worse than in oligodendrogliomas with *TERT* mutation. Cases with *TERT* mutation had a worse prognosis than cases without *TERT* mutation, but none of the relevant results in our study had statistical significance.

The combination of *TERTp* and *IDH* mutational status was a significant prognostic factor in grade II and III gliomas; this finding of a specific association between *IDH/ TERTp* group and low-grade glioma is consistent with results from a previous study (20, 29). Eckel-Passow et al. (12) showed that patients with *IDH-WT/TERTp-WT* have poorer overall survival when compared with patients with *IDH-mutated/TERTp* or *IDH* mutation alone, but showed better overall survival when compared with patients with *IDH-WT/TERTp-mutation* (11). A recently published meta-analysis also suggested that combined *TERTp-mutated/IDH-WT* testing could act as a significant biomarker for poor prognosis in grade II and III gliomas (20).

Given that 67.9% of tumours being *TERTp-mut*, *TERT* is the most frequently mutated gene in gliomas thus far identified (5, 8, 30-32). Our data confirm the high frequency of *TERTp-mutation* in gliomas, and show that these mutations clusterise into specific entities, with distinct clinical significances.

In previous studies, the 1p/19q co-deletion was strongly associated with mutations in *TERTp* (33, 34). In the present study, we found that 96.9% of patients with oligodendrogliomas had a *TERTp* mutation, whereas two patients with oligodendroglioma were *TERTp-WT*. On the contrary, there was a high frequency of *TERTp* mutation in cases with GBM that did not harbor the 1p/19q co-deletion, and therefore we conclude that the *TERTp* mutation is not exclusively associated with the 1p/19q co-deletion.

Regarding the *TERTp* mutation from a prognostic perspective in diffuse gliomas, previous studies have shown conflicting results. Labussiere et al. have found that *TERTp* mutations may be associated with poorer outcome in high-

grade gliomas (31), however, Pekmezci et al. have reported that *TERT*-mutants had significantly worse survival only in *IDH-WT* astrocytoma, which includes grades II and III (10). Such contradictory effects of *TERTp* mutation on patient outcome between groups have been reported previously (11). Aibaidula et al. found comparable results to those of Pekmezci et al., and concluded that adult *IDH-WT* lower-grade gliomas should be further classified by *TERTp* mutation status (35).

According to Cimpact now update 3, *IDH* wild type diffuse or anaplastic astrocytomas will have a worse prognosis as grade IV glioblastomas. The following molecular methods can be used to distinguish these cases: *EGFR* amplification, losses of chromosome 10 (whole chromosome, 10p or 10q), gains of chromosome 7 (whole chromosome, 7p or 7q), *TERT* promoter mutations, homozygous deletion of *CDKN2A/B*, and large-scale, microarray based DNA methylation profiling. According to the results of the current study, histologic *IDH-wildtype* diffuse astrocytic gliomas of WHO grade II or III that carry *EGFR* amplification, +7/-10 or *TERT* promoter mutation are associated with significantly shorter survival compared to patients with other WHO grade II or III gliomas, and outcomes are similar to those in patients with *IDH-wildtype* glioblastoma (27). Molecular studies other than *TERT* promoter mutation could not be performed, and this is a limitation of our study. We aim to fill this gap in future studies.

*IDH* mutation was detected in 16 cases with midline localization in our study and their grade was II. In these cases, which are known to have a good prognosis in follow-up, diffuse midline glioma was evaluated by considering it in the differential diagnosis. However, *H3F3A K27M* mutation could not be detected with immunohistochemical or molecular methods.

*TERT* promoter mutations were shown to have inverse prognostic effects in *IDH-mut* and *IDH-WT* WHO grade II/III gliomas. Our study strongly supports using *TERT* and *IDH* genotyping in WHO grade II/III gliomas as a reliable and reasonable test that can help clinicians predict patient outcome more precisely than using only conventional histology, or *TERT* or *IDH* status alone. It is important to note that gliomas with concurrent *TERT* promoter and *IDH* mutations are almost always accompanied with 1p19q co-deletion, which is the hallmark of oligodendroglioma according to the WHO classification 2016, and it can help to explain why gliomas with coexisting *IDH* and *TERT* promoter mutations are most likely associated with favorable outcome.

Data suggest that patients with *TERT* promoter mutations in tumors probably require more aggressive treatment than their WT counterparts. Further studies will help elucidating the value of *TERT* promoter mutations as biomarkers in clinical practice and eventual therapeutic targets. Expression data and an association with shorter telomeres already strongly indicate the role of the *TERT* promoter mutations not only in glioma, but in many other cancer types, and future functional studies will aid in placing the *TERT* promoter mutations into the right context.

#### Acknowledgement

The statistical part of the study was conducted by specialist pediatrician doctor Ersin Tural.

#### Conflict of Interest

The authors declare that they have no conflict of interest.

#### Funding

This study was supported by the University of Health Sciences Scientific Research Unit (Project number 2018/064).

#### Authorship Contributions

Concept: NKT, IY, BO, Design: NKT, IY, BO, Data collection or processing: NKT, Analysis or Interpretation: NKT, IY, BO, Literature search: NKT, IY, BO, Writing: NKT, IY, BO, Approval: NKT, IY, BO.

## REFERENCES

- Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of tumors of the central nervous system: A summary. *Acta Neuropathol.* 2016;131:803-20.
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathol.* 2007;114:97-109.
- Vuong HG, Altibi AMA, Duong UNP, Ngo HTT, Pham TQ, Chan AK, Park CK, Fung KM, Hassell L. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data. *Crit Rev Oncol Hematol.* 2017;120:1-9.
- Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R. TERT promoter mutations in familial and sporadic melanoma. *Science.* 2013; 339:959-61.
- Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, Ichimura K. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. *Acta Neuropathol.* 2013;126:267-76.
- Otani R, Uzuka T, Ueki K. Classification of adult diffuse gliomas by molecular markers-a short review with historical footnote. *Jpn J Clin Oncol.* 2017;47:2-6.
- Pesenti C, Paganini L, Fontana L, Veniani E, Runza L, Ferrero S, Bosari S, Menghi M, Marfia G, Caroli M, Silipigni R, Guernerri S, Tabano S, Miozzo M. Mass spectrometry-based assay for the molecular diagnosis of glioma: Concomitant detection of chromosome 1p/19q codeletion, and IDH1, IDH2, and TERT mutation status. *Oncotarget.* 2017;8:57134-48.
- Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, Yang R, Diplas BH, Wang Z, Greer PK, Zhu H, Wang CY, Carpenter AB, Friedman H, Friedman AH, Keir ST, He J, He Y, McLendon RE, Herndon JE 2nd, Yan H, Bigner DD. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. *Oncotarget.* 2014;5:1515-25.
- Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG Jr, Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhi R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH; TCGA Research Network, Nushmehr H, Iavarone A, Verhaak RG. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. *Cell.* 2016;164:550-63.
- Pekmezci M, Rice T, Molinaro AM, Walsh KM, Decker PA, Hansen H, Sicotte H, Kollmeyer TM, McCoy LS, Sarkar G, Perry A, Giannini C, Tihan T, Berger MS, Wiemels JL, Bracci PM, Eckel-Passow JE, Lachance DH, Clarke J, Taylor JW, Luks T, Wiencke JK, Jenkins RB, Wrensch MR. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: Additional prognostic roles of ATRX and TERT. *Acta Neuropathol.* 2017;133:1001-16.
- Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O'Neill BP, Buckner JC, Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD, Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. *N Engl J Med.* 2015;372:2499-508.
- Labreche K, Kinnersley B, Berzero G, Di Stefano AL, Rahimian A, Detrait I, Marie Y, Grenier-Boley B, Hoang-Xuan K, Delattre JY, Idubai A, Houlston RS, Sanson M. Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci. *Acta Neuropathol.* 2018;135:743-55.
- Masui K, Mischel PS, Reifenberger G. Molecular classification of gliomas. *Handb Clin Neurol.* 2016;134:97-120.
- Reuss DE, Sahn F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DT, Hovestadt V, Mittelbronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, Weller M, Wick W, Pfister SM, von Deimling A. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. *Acta Neuropathol.* 2015;129:133-46.



15. Roshandel AK, Busch CM, Mullekom JV, Cuoco JA, Rogers CM, Apfel LS, Marvin EA, Sontheimer HW, Umans RA. The predictive capability of immunohistochemistry and DNA sequencing for determining TP53 functional mutation status: A comparative study of 41 glioblastoma patients. *Oncotarget*. 2019;10:6204-18.
16. Walsh KM, Wiencke JK, Lachance DH, Wiemels JL, Molinaro AM, Eckel-Passow JE, Jenkins RB, Wrensch MR. Telomere maintenance and the etiology of adult glioma. *Neuro Oncol*. 2015;17:1445-52.
17. You H, Wu Y, Chang K, Shi X, Chen XD, Yan W, Li R. Paradoxical prognostic impact of TERT promoter mutations in gliomas depends on different histological and genetic backgrounds. *CNS Neurosci Ther*. 2017;23:790-7.
18. Zhou P, Wei L, Xia X, Shao N, Qian X, Yang Y. Association between telomerase reverse transcriptase rs2736100 polymorphism and risk of glioma. *J Surg Res*. 2014;191:156-60.
19. Gillis AJ, Schuller AP, Skordalakes E. Structure of the *Tribolium castaneum* telomerase catalytic subunit TERT. *Nature*. 2008;455:633-7.
20. Stewart SA, Weinberg RA. Telomeres: Cancer to human aging. *Annu Rev Cell Dev Biol*. 2006;22:531-57.
21. Kim HS, Kwon MJ, Song JH, Kim ES, Kim HY, Min KW. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas. *Pathol Res Pract*. 2018;214:881-8.
22. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovannella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih IeM, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. *Proc Natl Acad Sci U S A*. 2013;110:6021-6.
23. Yang P, Cai J, Yan W, Zhang W, Wang Y, Chen B, Li G, Li S, Wu C, Yao K, Li W, Peng X, You Y, Chen L, Jiang C, Qiu X, Jiang T; CGGA project. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. *Neuro Oncol*. 2016;18:1099-108.
24. Brandner S, von Deimling A. Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. *Neuropathol Appl Neurobiol*. 2015;41:694-720.
25. Neumann JE, Dorostkar MM, Korshunov A, Mawrin C, Koch A, Giese A, Schüller U. Distinct Histomorphology in Molecular Subgroups of Glioblastomas in Young Patients. *J Neuropathol Exp Neurol*. 2016;75:408-14.
26. Hewer E, Prebil N, Berezowska S, Gutt-Will M, Schucht P, Dettmer MS, Vassella E. Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting. *Virchows Arch*. 2017;471:641-9.
27. Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, Kleinschmidt-DeMasters BK, Perry A, Reifenberger G, Stupp R, von Deimling A, Weller M. cIMPACT-NOW update 3: Recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". *Acta Neuropathol*. 2018;136:805-10.
28. Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S, Suzuki K, Saito K, Kobayashi K, Higuchi F, Uzuka T, Otani R, Tamura K, Sumita K, Ohno M, Miyakita Y, Kagawa N, Hashimoto N, Hatae R, Yoshimoto K, Shinojima N, Nakamura H, Kanemura Y, Okita Y, Kinoshita M, Ishibashi K, Shofuda T, Kodama Y, Mori K, Tomogane Y, Fukai J, Fujita K, Terakawa Y, Tsuyuguchi N, Moriuchi S, Nonaka M, Suzuki H, Shibuya M, Maehara T, Saito N, Nagane M, Kawahara N, Ueki K, Yoshimine T, Miyaoka E, Nishikawa R, Komori T, Narita Y, Ichimura K. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. *Acta Neuropathol Commun*. 2016;4:79.
29. Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He Y, Yan H, Bigner DD, Oba-Shinjo SM, Marie SK, Riggins GJ, Kinzler KW, Vogelstein B, Hruban RH, Maitra A, Papadopoulos N, Meeker AK. Altered telomeres in tumors with ATRX and DAXX mutations. *Science*. 2011;333:425.
30. Chan AK, Yao Y, Zhang Z, Chung NY, Liu JS, Li KK, Shi Z, Chan DT, Poon WS, Zhou L, Ng HK. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. *Mod Pathol*. 2015;28:177-86.
31. Labussière M, Di Stefano AL, Gleize V, Boisselier B, Giry M, Mangesius S, Bruno A, Pattera R, Marie Y, Rahimian A, Finocchiaro G, Houlston RS, Hoang-Xuan K, Idbaih A, Delattre JY, Mokhtari K, Sanson M. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. *Br J Cancer*. 2014;111:2024-32.
32. Liu X, Wu G, Shan Y, Hartmann C, von Deimling A, Xing M. Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. *Cell Cycle*. 2013;12:1637-8.
33. Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, Renard MA, Iraqi W, Idbaih A, Paris S, Capelle L, Duffau H, Cornu P, Simon JM, Mokhtari K, Polivka M, Omuro A, Carpentier A, Sanson M, Delattre JY, Hoang-Xuan K. Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome. *Neurology*. 2007;68:1831-6.
34. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sips L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up of EORTC brain tumor group study 26951. *J Clin Oncol*. 2013;31:344-50.
35. Aibaidula A, Chan AK, Shi Z, Li Y, Zhang R, Yang R, Li KK, Chung NY, Yao Y, Zhou L, Wu J, Chen H, Ng HK. Adult IDH wild-type lower-grade gliomas should be further stratified. *Neuro Oncol*. 2017;19:1327-37.